Amalgamated Financial’s Gilead Sciences GILD Stock Holding History

Amalgamated Financial’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$18.8M	Buy	+315,473	New	+$20.2M	0.15%	107

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's GILD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Gilead Sciences (GILD) in Q1 2022: 315,473 shares worth $18.8M. The stake represents 0.15% of the portfolio and ranks #107 among its holdings.

1,601 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

Amalgamated Financial held 315,473 shares of Gilead Sciences worth $18.8M as of Q1 2022.
Gilead Sciences was a new Amalgamated Financial position in Q1 2022.
Gilead Sciences made up 0.15% of Amalgamated Financial's portfolio in Q1 2022, its #107 holding.
1,601 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.